Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A study of patients with colorectal cancer that have a genetic abnormality in the BRAF gene taking encorafenib plus cetuximab with or withou… Ended

2023-509405-77-00 Colorectal cancer (BRAF V600E-mutant mCRC) 5 2021-02-16
A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in C… Ended

2023-509604-15-00 Advanced Renal Cell Carcinoma 3 2021-02-15
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended

2022-500439-35-00 treatment-naive chronic lymphocytic leukemia 5 2021-02-11
Patritumab Deruxtecan in Subjects with Metastatic or Locally Advanced EGFR-mutated NSCLC Ended

2024-512238-13-00 Metastatic or Locally Advanced EGFR mutated Non-Small C 4 2021-02-10
A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma. Ended

2024-514775-17-00 Malignant B-cell lymphoma 4 2021-02-10
Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations. Ended

2024-515149-41-00 Advanced Hematologic Malignancies 1 2021-02-04
FIBRAPLO - Haplo-identical transplantation in patients with myleofibrosis Ended

2024-513325-23-00 Myelofibrosis 4 2021-02-03
This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Pat… Ended

2023-507338-26-00 Histologically documented gastric or gastroesophageal j 5 2021-02-01
Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) Ended

2024-511929-60-00 Waldenström’s Macroglobulinemia 4 2021-01-28
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o… Ended

2023-505309-18-00 HER2-positive Metastatic Breast Cancer 9 2021-01-21
Encorafenib in combination with Binimetinib in Patients with BRAFV600E mutant metastatic Lung Cancer Ended

2024-515944-22-00 BRAFV600E-mutant metastatic Non-small Cell Lung Cancer 4 2021-01-19
A Phase 1 Study on the effects of LY3410738 (study drug) administered to Patients with Advanced Solid Tumors with IDH1 or IDH2 Mutations Ended

2024-515150-24-00 Patients with IDH1 R132, IDH2 R140 or IDH2 R172-mutant 1 2021-01-19
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced NSCLC… Ended

2023-507475-21-00 Lung Cancer, Non-Small Cell 10 2021-01-18
MASTER Ended

2024-515404-39-00 Breast cancer 5 2021-01-14
"Study of chemotherapy vs immunotherapy for patients with lung cancer bounded in the thorax and completely resected" Ended

2024-513730-38-00 Resectable Non-small cell lung cancer 5 2021-01-13
A phase II, open-label study improving compliance and time of treatment after obtaining complete response through a tailored schedule of son… Ended

2024-516797-29-00 locally advanced basal cell carcinoma 4 2021-01-12
Blood-borne Assessment of Stromal activation in esophageAL adenocarcinoma to guide tocilizumab Therapy: a randomized phase II proof-of-conce… Ended

2023-509458-77-00 Esophageal adenocarcinoma, esophageal cancer 4 2021-01-04
Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Diffuse Large B-Cell Lymphoma Ended

2024-513616-95-00 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR D 10 2020-12-22
A clinical study of different treatments for kidney cancer (MK-3475-03B) Ended

2023-506839-15-00 Renal cell carcinoma 9 2020-12-21
First-in-human Study to Test Safety and Anti-tumor Activity of a Novel Drug for Patients with Advanced Solid Tumor Harboring Genetic Alterat… Ended

2023-510450-16-00 Phase 1: Advanced solid tumors harboring genetic altera 1 2020-12-16
A study on the efficacy and safety of cisplatin/etoposide and concomitant radiotherapy in combination with durvalumab, an immunotherapy, in … Ended

2024-513433-20-00 Limited Disease Small Cell Lung Cancer 4 2020-12-16
A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended

2023-504830-23-00 B-cell Lymphoma 5 2020-12-16
GYNET : A randomized, multicenter, open label, Phase I/II study to evaluate the safety (Phase I - safety run in), clinical and biological ac… Ended

2024-510714-32-00 Patiens with locally advanced/metastatic endometrial ca 4 2020-12-10
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed … Ended

2023-504959-27-00 Participants with Limited Stage-Small Cell Lung Cancer, 5 2020-12-09